MX2015011131A - Composiciones, formulaciones y metodos para tratar enfermedades oculares. - Google Patents
Composiciones, formulaciones y metodos para tratar enfermedades oculares.Info
- Publication number
- MX2015011131A MX2015011131A MX2015011131A MX2015011131A MX2015011131A MX 2015011131 A MX2015011131 A MX 2015011131A MX 2015011131 A MX2015011131 A MX 2015011131A MX 2015011131 A MX2015011131 A MX 2015011131A MX 2015011131 A MX2015011131 A MX 2015011131A
- Authority
- MX
- Mexico
- Prior art keywords
- formulations
- compositions
- methods
- ocular diseases
- treating ocular
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 238000009472 formulation Methods 0.000 title abstract 2
- 208000022873 Ocular disease Diseases 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 101100481408 Danio rerio tie2 gene Proteins 0.000 abstract 1
- 101100481410 Mus musculus Tek gene Proteins 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 238000002648 combination therapy Methods 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/28—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Ophthalmology & Optometry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Se describen en la presente compuestos efectivos para la activación de Tie-2 e inhibición de HPTP-beta. Los compuestos pueden proporcionar una terapia efectiva para condiciones asociadas con la angiogénesis, por ejemplo, condiciones oculares. Se describen formulaciones de solubilidad incrementada. También se describe la terapia de combinación con anticuerpos y datos de PK/PD.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361792679P | 2013-03-15 | 2013-03-15 | |
US201361792868P | 2013-03-15 | 2013-03-15 | |
US201361882048P | 2013-09-25 | 2013-09-25 | |
US201361882056P | 2013-09-25 | 2013-09-25 | |
US201461934570P | 2014-01-31 | 2014-01-31 | |
PCT/US2014/029723 WO2014145068A1 (en) | 2013-03-15 | 2014-03-14 | Compositions, formulations and methods for treating ocular diseases |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2015011131A true MX2015011131A (es) | 2016-03-04 |
MX371382B MX371382B (es) | 2020-01-28 |
Family
ID=51529957
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015011131A MX371382B (es) | 2013-03-15 | 2014-03-14 | Composiciones, formulaciones y metodos para tratar enfermedades oculares. |
Country Status (17)
Country | Link |
---|---|
US (10) | US9440963B2 (es) |
EP (3) | EP3607821B1 (es) |
JP (3) | JP6572201B2 (es) |
KR (1) | KR20150129019A (es) |
CN (2) | CN109925312A (es) |
AU (2) | AU2014233363B2 (es) |
BR (1) | BR112015023753A2 (es) |
CA (1) | CA2903871A1 (es) |
ES (2) | ES2766326T3 (es) |
GB (3) | GB2549865B (es) |
HK (2) | HK1206558A1 (es) |
IL (2) | IL240786B (es) |
MX (1) | MX371382B (es) |
MY (1) | MY171945A (es) |
PH (2) | PH12015502153B1 (es) |
SG (1) | SG11201507131WA (es) |
WO (1) | WO2014145068A1 (es) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20110122881A (ko) | 2006-04-07 | 2011-11-11 | 워너 칠콧 컴퍼니 엘엘씨 | 인간 단백질 타이로신 포스파타아제 베타(hptp베타)에 결합하는 항체 및 그의 용도 |
US7622593B2 (en) | 2006-06-27 | 2009-11-24 | The Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
JP5536113B2 (ja) | 2009-07-06 | 2014-07-02 | アケビア セラピューティクス インコーポレイテッド | がん細胞の転移を予防するための化合物、組成物および方法 |
MY150626A (en) | 2009-10-30 | 2014-02-07 | Ix Biopharma Ltd | Fast dissolving solid dosage form |
IN2012DN04950A (es) | 2009-11-06 | 2015-09-25 | Aerpio Therapeutics Inc | |
US20180092883A1 (en) * | 2010-10-07 | 2018-04-05 | Aerpio Therapeutics, Inc. | Phosphatase inhibitors for treating ocular diseases |
ES2748519T3 (es) | 2010-12-08 | 2020-03-17 | Convatec Technologies Inc | Accesorio de sistema de exudado de heridas |
JP5965409B2 (ja) | 2010-12-08 | 2016-08-03 | コンバテック・テクノロジーズ・インコーポレイテッドConvatec Technologies Inc | 創傷滲出液を評価するための統合システム |
AU2012323856B2 (en) | 2011-10-13 | 2017-05-25 | EyePoint Pharmaceuticals, Inc. | Methods for treating Vascular Leak Syndrome and cancer |
EP3501536A1 (en) | 2011-10-13 | 2019-06-26 | Aerpio Therapeutics, Inc. | Treatment of ocular disease |
NZ706302A (en) * | 2012-10-11 | 2017-07-28 | Ix Biopharma Ltd | Sublingual wafer solid dosage form containing amylopectin |
WO2014145068A1 (en) * | 2013-03-15 | 2014-09-18 | Aerpio Therapeutics Inc. | Compositions, formulations and methods for treating ocular diseases |
US20150050277A1 (en) | 2013-03-15 | 2015-02-19 | Aerpio Therapeutics Inc. | Compositions and methods for treating ocular diseases |
JP6549140B2 (ja) | 2014-02-19 | 2019-07-24 | エアーピオ セラピューティクス インコーポレイテッド | N−ベンジル−3−ヒドロキシ−4−置換ピリジン−2−(1h)−オン |
JP6483148B2 (ja) | 2014-03-14 | 2019-03-13 | エアーピオ セラピューティクス インコーポレイテッド | HPTP−β阻害剤 |
US9539245B2 (en) | 2014-08-07 | 2017-01-10 | Aerpio Therapeutics, Inc. | Combination of immunotherapies with activators of Tie-2 |
CN108290057A (zh) * | 2015-09-23 | 2018-07-17 | 爱尔皮奥治疗有限公司 | 用tie-2的激活剂治疗眼内压的方法 |
CN108141741B (zh) * | 2015-11-06 | 2020-04-14 | 华为技术有限公司 | 一种语音漫游方法,移动性管理网元及接入网网元 |
WO2018017714A1 (en) | 2016-07-20 | 2018-01-25 | Aerpio Therapeutics, Inc. | HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß) |
CN109996440A (zh) * | 2016-10-21 | 2019-07-09 | 曼宁研究有限公司 | Ve-ptp敲除 |
US10894824B2 (en) | 2018-09-24 | 2021-01-19 | Aerpio Pharmaceuticals, Inc. | Multispecific antibodies that target HPTP-β (VE-PTP) and VEGF |
CA3137138A1 (en) * | 2019-04-18 | 2020-10-22 | EyePoint Pharmaceuticals, Inc. | Methods of treating hypertension with activators of tie-2 |
JP2022530657A (ja) | 2019-04-29 | 2022-06-30 | アイポイント ファーマシューティカルズ, インコーポレイテッド | シュレム管を標的とするTie-2活性化物質 |
US11413242B2 (en) | 2019-06-24 | 2022-08-16 | EyePoint Pharmaceuticals, Inc. | Formulations of Tie-2 activators and methods of use thereof |
CN114901278A (zh) | 2019-10-29 | 2022-08-12 | 视点制药公司 | Tie-2的小分子激活剂 |
EP4164690A1 (en) * | 2020-06-16 | 2023-04-19 | Amy Ripka | Small molecule ve-ptp inhibitors |
AU2021400315A1 (en) * | 2020-12-18 | 2023-07-06 | EyePoint Pharmaceuticals, Inc. | Methods for manufacture of small molecule activators of tie-2 |
Family Cites Families (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5078486A (en) | 1989-10-13 | 1992-01-07 | Evans David W | Self-calibrating vision test apparatus |
US5688781A (en) * | 1994-08-19 | 1997-11-18 | Bristol-Myers Squibb Company | Method for treating vascular leak syndrome |
EP0821728B1 (en) | 1995-04-06 | 2004-08-11 | Regeneron Pharmaceuticals, Inc. | Tie-2 ligands, methods of making and uses thereof |
US6455031B1 (en) * | 1997-06-18 | 2002-09-24 | David G Davies | Methods and compositions for controlling biofilm development |
US6455035B1 (en) * | 1999-03-26 | 2002-09-24 | Regeneron Pharmaceuticals, Inc. | Angiopoietins and methods of use thereof |
US6924264B1 (en) * | 1999-04-30 | 2005-08-02 | Amylin Pharmaceuticals, Inc. | Modified exendins and exendin agonists |
HUP0401811A2 (hu) * | 2000-12-11 | 2004-12-28 | Takeda Chemical Industries, Ltd. | Javított vízoldékonyságú gyógyszerkészítmény és eljárás az előállítására |
SE518981C2 (sv) | 2000-12-14 | 2002-12-17 | Shl Medical Ab | Autoinjektor |
US7166435B2 (en) * | 2001-08-06 | 2007-01-23 | The Quigley Corporation | Compositions and methods for reducing the transmissivity of illnesses |
US20030158199A1 (en) * | 2002-01-25 | 2003-08-21 | Kylix, B.V. | Novel compounds for inhibition of Tie-2 |
EP1572083A4 (en) | 2002-04-25 | 2008-09-24 | Univ Connecticut Health Ct | USE OF THERMAL SHOCK PROTEINS TO IMPROVE THE THERAPEUTIC ADVANTAGE OF NON-VACCINAL TREATMENT MODALITY |
US7226755B1 (en) | 2002-09-25 | 2007-06-05 | The Procter & Gamble Company | HPTPbeta as a target in treatment of angiogenesis mediated disorders |
US7507568B2 (en) | 2002-09-25 | 2009-03-24 | The Proctor & Gamble Company | Three dimensional coordinates of HPTPbeta |
AU2003279911A1 (en) * | 2002-10-09 | 2004-05-04 | Kosan Biosciences, Inc. | Therapeutic formulations |
US6930117B2 (en) | 2002-11-09 | 2005-08-16 | The Procter & Gamble Company | N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones |
US6946479B2 (en) | 2002-11-09 | 2005-09-20 | The Procter & Gamble Company | N-sulfonyl-4-methyleneamino-3-hydroxy-2-pyridones |
AU2003292838A1 (en) * | 2002-12-27 | 2004-07-29 | Kirin Beer Kabushiki Kaisha | Therapeutic agent for wet age-related macular degeneration |
JP4881725B2 (ja) * | 2003-04-09 | 2012-02-22 | エクセリクシス, インク. | Tie−2モジュレータと使用方法 |
NZ621449A (en) * | 2003-05-30 | 2015-07-31 | Genentech Inc | Treatment with anti-vegf antibodies |
US20050059639A1 (en) | 2003-09-11 | 2005-03-17 | Wei Edward T. | Ophthalmic compositions and method for treating eye discomfort and pain |
AU2005250188A1 (en) * | 2004-06-02 | 2005-12-15 | Valtion Teknillinen Tutkimuskeskus | Method for activating of T cell protein tyrosine phosphatase and therapeutical methods based thereon |
CN101415422B (zh) * | 2006-02-09 | 2012-11-07 | 第一三共株式会社 | 抗癌药用组合物 |
KR20110122881A (ko) | 2006-04-07 | 2011-11-11 | 워너 칠콧 컴퍼니 엘엘씨 | 인간 단백질 타이로신 포스파타아제 베타(hptp베타)에 결합하는 항체 및 그의 용도 |
US7795444B2 (en) | 2006-06-27 | 2010-09-14 | Warner Chilcott Company | Human protein tyrosine phosphatase inhibitors and methods of use |
US7622593B2 (en) | 2006-06-27 | 2009-11-24 | The Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
US20130023542A1 (en) | 2006-06-27 | 2013-01-24 | Aerpio Therapeutics Inc. | Human protein tyrosine phosphatase inhibitors and methods of use |
US8846685B2 (en) | 2006-06-27 | 2014-09-30 | Aerpio Therapeutics Inc. | Human protein tyrosine phosphatase inhibitors and methods of use |
US7589212B2 (en) | 2006-06-27 | 2009-09-15 | Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
WO2008027013A2 (en) * | 2006-08-29 | 2008-03-06 | National Cancer Centre | Combination of mtor antagonist and angiogenesis inhibitor for the treatment of cancer |
PT2076290T (pt) * | 2006-10-27 | 2017-01-17 | Sunnybrook Health Sciences Center | Agonistas de tie 2 multiméricos e utilizações dos mesmos na estimulação da angiogénese |
ES2365931T3 (es) | 2006-12-13 | 2011-10-13 | Shl Group Ab | Inyector automático. |
EP2131898B1 (en) | 2007-03-23 | 2017-08-30 | SHL Group AB | Auto injector |
EP2162170B1 (en) | 2007-07-06 | 2011-03-16 | SHL Group AB | One shot injector with dual springs |
AU2008300703B2 (en) | 2007-09-18 | 2011-03-17 | Shl Group Ab | Automatic injection device with needle insertion |
EP2269621B1 (en) * | 2008-03-31 | 2017-12-27 | Shiseido Company, Ltd. | Cinnamonum extract for treating photoaging |
WO2009141219A1 (en) | 2008-05-20 | 2009-11-26 | Shl Group Ab | Device for a medicament delivery device |
AU2009256710B2 (en) | 2008-06-11 | 2012-04-19 | Shl Group Ab | Medicament delivery device |
KR20110027659A (ko) * | 2008-06-18 | 2011-03-16 | 가부시키가이샤 시세이도 | 림프관의 안정화제 |
JP4751482B2 (ja) * | 2008-07-22 | 2011-08-17 | 株式会社メニコン | コンタクトレンズ用液剤 |
TR201809280T4 (tr) | 2009-01-12 | 2018-07-23 | Aerpio Therapeutics Inc | Vasküler sızıntı sendromunun tedavi edilmesine yönelik yöntemler. |
US9096555B2 (en) | 2009-01-12 | 2015-08-04 | Aerpio Therapeutics, Inc. | Methods for treating vascular leak syndrome |
JP5536113B2 (ja) | 2009-07-06 | 2014-07-02 | アケビア セラピューティクス インコーポレイテッド | がん細胞の転移を予防するための化合物、組成物および方法 |
US8883832B2 (en) | 2009-07-06 | 2014-11-11 | Aerpio Therapeutics Inc. | Compounds, compositions, and methods for preventing metastasis of cancer cells |
TWI393578B (zh) | 2009-07-07 | 2013-04-21 | Shl Group Ab | 注射裝置 |
TW201105363A (en) * | 2009-07-14 | 2011-02-16 | Univ Yamagata | Eye drop for macular edema treatment |
IN2012DN04950A (es) | 2009-11-06 | 2015-09-25 | Aerpio Therapeutics Inc | |
JP2011201811A (ja) * | 2010-03-25 | 2011-10-13 | Shiseido Co Ltd | Tie2活性化剤、血管の成熟化、正常化又は安定化剤、リンパ管安定化剤並びにしわ防止・改善剤及びむくみ改善・予防剤 |
US20110319455A1 (en) | 2010-04-19 | 2011-12-29 | Bruce Steven Klein | Antifungal Treatment |
WO2011134056A1 (en) * | 2010-04-28 | 2011-11-03 | Sunnybrook Health Sciences Centre | Methods and uses of tie2 binding and/or activating agents |
CA2890554A1 (en) * | 2010-10-07 | 2012-04-12 | Aerpio Therapeutics Inc. | Compositions and methods for treating ocular edema, neovascularization and related diseases |
EP2647385A4 (en) * | 2010-12-02 | 2014-04-30 | Maruzen Pharm Co Ltd | TIE2 ACTIVATOR, VASCULAR ENDOTHELIAL CELL GROWTH FACTOR (VEGF), ANTI-ANGIOGENESIS AGENT, MEANS FOR REINFORCING BLOOD VESSELS, MEANS FOR THE NORMALIZATION OF BLOOD VESSELS, DEVICES FOR STABILIZING BLOOD VESSELS AND PHARMACEUTICAL COMPOSITION |
CN102532042A (zh) * | 2010-12-30 | 2012-07-04 | 上海医药工业研究院 | 一种芳基脲类化合物、其中间体及其应用 |
RU2013138180A (ru) * | 2011-02-11 | 2015-03-20 | Псивида Юэс, Инк. | Способы лечения макулярного отека с использованием противоотечных лекарственных средств |
EP3501536A1 (en) | 2011-10-13 | 2019-06-26 | Aerpio Therapeutics, Inc. | Treatment of ocular disease |
AU2012323856B2 (en) | 2011-10-13 | 2017-05-25 | EyePoint Pharmaceuticals, Inc. | Methods for treating Vascular Leak Syndrome and cancer |
US20150050277A1 (en) * | 2013-03-15 | 2015-02-19 | Aerpio Therapeutics Inc. | Compositions and methods for treating ocular diseases |
WO2014145068A1 (en) | 2013-03-15 | 2014-09-18 | Aerpio Therapeutics Inc. | Compositions, formulations and methods for treating ocular diseases |
JP6549140B2 (ja) | 2014-02-19 | 2019-07-24 | エアーピオ セラピューティクス インコーポレイテッド | N−ベンジル−3−ヒドロキシ−4−置換ピリジン−2−(1h)−オン |
JP6483148B2 (ja) | 2014-03-14 | 2019-03-13 | エアーピオ セラピューティクス インコーポレイテッド | HPTP−β阻害剤 |
US9719135B2 (en) * | 2014-07-03 | 2017-08-01 | Mannin Research Inc. | Conditional angiopoietin-1/angiopoietin-2 double knock-out mice with defective ocular drainage system |
-
2014
- 2014-03-14 WO PCT/US2014/029723 patent/WO2014145068A1/en active Application Filing
- 2014-03-14 ES ES14762974T patent/ES2766326T3/es active Active
- 2014-03-14 KR KR1020157029411A patent/KR20150129019A/ko not_active Application Discontinuation
- 2014-03-14 AU AU2014233363A patent/AU2014233363B2/en active Active
- 2014-03-14 CN CN201910221542.4A patent/CN109925312A/zh active Pending
- 2014-03-14 CN CN201480028572.9A patent/CN105307498B/zh active Active
- 2014-03-14 GB GB1709419.4A patent/GB2549865B/en active Active
- 2014-03-14 US US13/999,670 patent/US9440963B2/en active Active
- 2014-03-14 CA CA2903871A patent/CA2903871A1/en not_active Abandoned
- 2014-03-14 MX MX2015011131A patent/MX371382B/es active IP Right Grant
- 2014-03-14 GB GB1411935.8A patent/GB2516561B/en active Active
- 2014-03-14 EP EP19174479.6A patent/EP3607821B1/en active Active
- 2014-03-14 SG SG11201507131WA patent/SG11201507131WA/en unknown
- 2014-03-14 BR BR112015023753A patent/BR112015023753A2/pt not_active Application Discontinuation
- 2014-03-14 JP JP2016503207A patent/JP6572201B2/ja active Active
- 2014-03-14 MY MYPI2015002288A patent/MY171945A/en unknown
- 2014-03-14 ES ES19174479T patent/ES2928162T3/es active Active
- 2014-03-14 GB GB1520656.8A patent/GB2540638B/en active Active
- 2014-03-14 EP EP14762974.5A patent/EP2967066B1/en active Active
- 2014-03-14 EP EP22171032.0A patent/EP4101297A1/en active Pending
-
2015
- 2015-07-27 HK HK15107185.3A patent/HK1206558A1/xx unknown
- 2015-08-24 IL IL240786A patent/IL240786B/en active IP Right Grant
- 2015-09-15 PH PH12015502153A patent/PH12015502153B1/en unknown
-
2016
- 2016-04-14 US US15/098,955 patent/US20160220540A1/en not_active Abandoned
- 2016-04-14 US US15/099,161 patent/US20160220541A1/en not_active Abandoned
- 2016-07-11 HK HK16108038.9A patent/HK1219836A1/zh unknown
-
2017
- 2017-02-27 US US15/443,622 patent/US20180022741A1/en not_active Abandoned
- 2017-09-28 AU AU2017235953A patent/AU2017235953B2/en not_active Expired - Fee Related
-
2018
- 2018-04-20 US US15/958,346 patent/US20180237429A1/en not_active Abandoned
- 2018-04-20 US US15/958,355 patent/US20180237430A1/en not_active Abandoned
- 2018-04-20 US US15/958,358 patent/US20180237431A1/en not_active Abandoned
- 2018-05-02 US US15/969,109 patent/US20180251457A1/en not_active Abandoned
-
2019
- 2019-07-11 IL IL267997A patent/IL267997A/en unknown
- 2019-08-09 JP JP2019147238A patent/JP6865254B2/ja active Active
- 2019-09-04 PH PH12019502018A patent/PH12019502018A1/en unknown
-
2020
- 2020-05-29 US US16/888,247 patent/US20200361926A1/en not_active Abandoned
-
2021
- 2021-04-05 JP JP2021064106A patent/JP7249374B2/ja active Active
-
2022
- 2022-03-03 US US17/685,802 patent/US20220274976A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12019502018A1 (en) | Compositions, formulations and methods for treating ocular diseases | |
PH12016501898A1 (en) | Quinoxaline derivatives useful as fgfr kinase modulators | |
EA201591612A1 (ru) | ПРИМЕНЕНИЕ ПИРАЗОЛПИРИМИДИНОВЫХ ПРОИЗВОДНЫХ ДЛЯ ЛЕЧЕНИЯ НАРУШЕНИЙ, СВЯЗАННЫХ С PI3Kδ | |
MX2016002544A (es) | Compuestos utiles como inmunomoduladores. | |
NZ724691A (en) | Quinoline derivatives as smo inhibitors | |
MX2016013689A (es) | Compuestos 4-amino-imidazoquinolina. | |
NZ724878A (en) | Compounds and compositions as toll-like receptor 7 agonists | |
EP3566750A3 (en) | Conjugates comprising cell-binding agents and cytotoxic agents | |
NZ720478A (en) | Autotaxin inhibitor compounds | |
MX2022007436A (es) | Inhibidores de la autotaxina y sus usos. | |
MX2016009663A (es) | Derivados de icariina. | |
MX2017005861A (es) | Metodos para el control transcripcional objetivo en regiones del super mejorador. | |
MX2018010993A (es) | Derivados de icariina e icaritina. | |
MX2016014436A (es) | Derivados de heterociclil-butanamida. | |
AU2018253600A1 (en) | Dosage forms and therapeutic uses of l-4-chlorokynurenine | |
WO2014134457A3 (en) | Conjugates comprising cell-binding agents and cytotoxic agents | |
MX2016008042A (es) | Derivados de imidazopirazinona. | |
MY180844A (en) | Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions | |
MX2018005987A (es) | Compuestos heterociclicos para el tratamiento de enfermedades. | |
WO2014134486A3 (en) | Conjugates comprising cell-binding agents and cytotoxic agents | |
MX2015016760A (es) | Derivados de ftalazina. | |
MX2017005669A (es) | Derivados de hidroxido de bencilo, preparacion de los mismos y uso terapeutico de los mismos. | |
PH12016500824A1 (en) | Compositions and methods for the treatment of viral diseases with pde4 modulators | |
MX2015012393A (es) | Derivados oxindol con un sustituyente oxetano y uso de los mismos para tratar enfermedades relacionadas con la vasopresina. | |
UA112552C2 (uk) | Гетероцикліламіни як інгібітори pi3k |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |